Association of Serum Sclerostin Levels with Marrow Adiposity in Postmenopausal Women with Glucocorticoid-induced Osteoporosis

Overview

Journal BMC Endocr Disord

Publisher Biomed Central

Specialty Endocrinology

Date 2024 Apr 28

PMID 38679740

Authors

Wei Li

Wei Wang

Minlan Zhang

Qi Chen

Fengyi Li

Shaojun Li

Affiliations

Soon will be listed here.

Abstract

Background: Glucocorticoids and sclerostin act as inhibitors of the Wnt signaling pathway, thereby hindering bone formation. Given the pathway's intricate association with mesenchymal stem cells, the hypothesis suggests that heightened sclerostin levels may be intricately linked to an augmentation in marrow adiposity induced by glucocorticoids. This study endeavored to delve into the nuanced relationship between circulating sclerostin and bone marrow adipose tissue in postmenopausal women grappling with glucocorticoid-induced osteoporosis (GIO).

Methods: In this cross-sectional study, 103 patients with autoimmune-associated diseases underwent glucocorticoid treatment, boasting an average age of 61.3 years (standard deviation 7.1 years). The investigation encompassed a thorough assessment, incorporating medical history, anthropometric data, biochemical analysis, and dual-energy X-ray absorptiometry measurements of lumbar and femoral bone mineral density (BMD). Osteoporosis criteria were established at a T-score of -2.5 or lower. Additionally, MR spectroscopy quantified the vertebral marrow fat fraction.

Results: BMD at the femoral neck, total hip, and lumbar spine showcased an inverse correlation with marrow fat fraction (r = -0.511 to - 0.647, P < 0.001). Serum sclerostin levels exhibited a positive correlation with BMD at various skeletal sites (r = 0.476 to 0.589, P < 0.001). A noteworthy correlation emerged between circulating sclerostin and marrow fat fraction at the lumbar spine (r = -0.731, 95% CI, -0.810 to -0.627, P < 0.001). Multivariate analysis brought to light that vertebral marrow fat fraction significantly contributed to sclerostin serum concentrations (standardized regression coefficient ß = 0.462, P < 0.001). Even after adjusting for age, body mass index, physical activity, renal function, BMD, and the duration and doses of glucocorticoid treatment, serum sclerostin levels maintained a significant correlation with marrow fat fraction.

Conclusions: Circulating sclerostin levels exhibited a noteworthy association with marrow adiposity in postmenopausal women grappling with GIO.

References

Li X, Ominsky M, Villasenor K, Niu Q, Asuncion F, Xia X . Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis. Endocrinology. 2017; 159(1):260-271. DOI: 10.1210/en.2017-00794. View

Durosier C, van Lierop A, Ferrari S, Chevalley T, Papapoulos S, Rizzoli R . Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. J Clin Endocrinol Metab. 2013; 98(9):3873-83. DOI: 10.1210/jc.2013-2113. View

Urano T, Shiraki M, Ouchi Y, Inoue S . Association of circulating sclerostin levels with fat mass and metabolic disease--related markers in Japanese postmenopausal women. J Clin Endocrinol Metab. 2012; 97(8):E1473-7. DOI: 10.1210/jc.2012-1218. View

Thiele S, Hannemann A, Winzer M, Baschant U, Weidner H, Nauck M . Regulation of sclerostin in glucocorticoid-induced osteoporosis (GIO) in mice and humans. Endocr Connect. 2019; 8(7):923-934. PMC: 6612066. DOI: 10.1530/EC-19-0104. View

Guanabens N, Gifre L, Peris P . The role of Wnt signaling and sclerostin in the pathogenesis of glucocorticoid-induced osteoporosis. Curr Osteoporos Rep. 2014; 12(1):90-7. DOI: 10.1007/s11914-014-0197-0. View

Li S, Wang B, Liang W, Chen Q, Wang W, Mei J . Associations Between Vertebral Marrow Proton Density Fat Fraction and Risk of Prostate Cancer. Front Endocrinol (Lausanne). 2022; 13:874904. PMC: 9047738. DOI: 10.3389/fendo.2022.874904. View

Kim J, Roh E, Hong S, Lee Y, Kim N, Yoo H . Association of serum sclerostin levels with low skeletal muscle mass: The Korean Sarcopenic Obesity Study (KSOS). Bone. 2019; 128:115053. DOI: 10.1016/j.bone.2019.115053. View

Ardawi M, Al-Kadi H, Rouzi A, Qari M . Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res. 2011; 26(12):2812-22. DOI: 10.1002/jbmr.479. View

Patalong-Wojcik M, Golara A, Zajac K, Sokolowska A, Kozlowski M, Toloczko-Grabarek A . Influence of Muscle Mass and Strength on Bone Mineralisation with Consideration of Sclerostin Concentration. Biomedicines. 2023; 11(6). PMC: 10295770. DOI: 10.3390/biomedicines11061574. View

10.

Courtalin M, Bertheaume N, Badr S, During A, Lombardo D, Deken V . Relationships between Circulating Sclerostin, Bone Marrow Adiposity, Other Adipose Deposits and Lean Mass in Post-Menopausal Women. Int J Mol Sci. 2023; 24(6). PMC: 10053867. DOI: 10.3390/ijms24065922. View

11.

Wanby P, Nobin R, Von S, Brudin L, Carlsson M . Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls. J Endocrinol Invest. 2016; 39(8):855-63. DOI: 10.1007/s40618-015-0421-5. View

12.

Ren H, Liang D, Jiang X, Tang J, Cui J, Wei Q . Variance of spinal osteoporosis induced by dexamethasone and methylprednisolone and its associated mechanism. Steroids. 2015; 102:65-75. DOI: 10.1016/j.steroids.2015.07.006. View

13.

Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico R . Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab. 2010; 95(5):2248-53. DOI: 10.1210/jc.2010-0067. View

14.

Sato A, Cregor M, Delgado-Calle J, Condon K, Allen M, Peacock M . Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin. J Bone Miner Res. 2016; 31(10):1791-1802. PMC: 8499032. DOI: 10.1002/jbmr.2869. View

15.

Fan J, Zhang D, Jiang Y, Yu L, Han B, Qian Z . The effects of PPARγ inhibitor on bones and bone marrow fat in aged glucocorticoid-treated female rats. Exp Gerontol. 2023; 181:112281. DOI: 10.1016/j.exger.2023.112281. View

16.

Wang Y, Khelifi N, De Halleux C, Ung R, Samson F, Gagnon C . Bone Marrow Adiposity, Bone Mineral Density and Wnt/β-catenin Pathway Inhibitors Levels in Hemodialysis Patients. J Bone Metab. 2022; 29(2):113-122. PMC: 9208902. DOI: 10.11005/jbm.2022.29.2.113. View

17.

Sharma-Ghimire P, Buchanan S, Bemben M, Knehans A, Campbell J, Bemben D . Sclerostin and Dickkopf-1 Characteristics According to Age and Physical Activity Levels in Premenopausal Women. J Clin Densitom. 2021; 25(2):168-177. DOI: 10.1016/j.jocd.2021.07.008. View

18.

van Lierop A, van der Eerden A, Hamdy N, Hermus A, den Heijer M, Papapoulos S . Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment. J Clin Endocrinol Metab. 2012; 97(10):E1953-7. PMC: 3462943. DOI: 10.1210/jc.2012-2218. View

19.

Sorensen N, Andreasen C, Jensen P, Hauge E, Bollerslev J, Delaisse J . Disturbed bone marrow adiposity in patients with Cushing's syndrome and glucocorticoid- and postmenopausal- induced osteoporosis. Front Endocrinol (Lausanne). 2023; 14:1232574. PMC: 10597666. DOI: 10.3389/fendo.2023.1232574. View

20.

Ma Y, Schwartz A, Sigurdsson S, Hue T, Lang T, Harris T . Circulating sclerostin associated with vertebral bone marrow fat in older men but not women. J Clin Endocrinol Metab. 2014; 99(12):E2584-90. PMC: 4255105. DOI: 10.1210/jc.2013-4493. View